Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6

Next Previous
Trial Profile

A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPI 613 (Primary)
  • Indications B-cell lymphoma; Burkitt's lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Dec 2019 According to a Rafael Pharmaceuticals media release, announced the expansion of its Phase 2 clinical trial of CPI-613 (devimistat) for patients with relapsed or refractory Burkitts lymphoma/leukemia.
    • 06 Nov 2019 According to the Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019), an interim analysis for toxicity will be conducted after the first 10 study participants have completed two complete cycles or have come off study.
    • 06 Nov 2019 Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top